“Metabolic Activation and Inactivation of Irinotecan when Combined with the Human Monoclonal Antibody Bevacizumab” (2013) Journal of Analytical Oncology, 2(4), pp.  218–225. doi:10.6000/1927-7229.2013.02.04.4.